Signatera™

Breast Cancer

Signatera™ may support personalized monitoring for breast cancer by tracking tumor-informed ctDNA over time, helping care teams evaluate molecular disease burden alongside imaging, pathology, and clinical assessment.

Covered by Medicare U.S.A. for Stage II-IV breast cancer in the neoadjuvant setting, regardless of subtype, and Stage IIb and higher breast cancer in the adjuvant and recurrence monitoring settings.

Lung Cancers

Signatera™ can help monitor ctDNA trends in lung cancer, supporting recurrence surveillance and response evaluation when used as part of a clinician-guided care plan.

Covered by Medicare U.S.A. for Stage I-III non-small cell lung cancer (NSCLC) in the surveillance setting.

Genitourinary Cancers

Personalized molecular residual disease (MRD) testing may provide additional insight for selected genitourinary cancers, including bladder cancer, by monitoring tumor-informed ctDNA after treatment.

Signatera™ is covered by Medicare U.S.A. for muscle invasive bladder cancer (MIBC) in the adjuvant and recurrence monitoring settings.

Head & Neck Cancers

For selected head and neck cancers, tumor-informed ctDNA monitoring may help clinicians follow molecular disease signals over time and support more informed discussions around surveillance and treatment response.

Lymphoma

Signatera™ can be used to help better manage your patient’s lymphoma with a more personalized approach to their care including assessing MRD status after completion of initial therapy to help predict relapse and identifying patients who are MRD-positive to inform additional treatments.

Skin Cancers

For selected skin cancers, including melanoma, Signatera™ may help monitor personalized ctDNA signals over time to support recurrence surveillance and treatment response assessment.

Sarcoma

Signatera™ may provide a personalized molecular monitoring option for selected sarcomas by tracking patient-specific tumor variants and supporting longitudinal assessment with the treating oncology team.

Gynecologic Cancers

Signatera™ may help monitor molecular residual disease signals in gynecologic cancers, supporting recurrence monitoring and care planning alongside standard clinical tools.

Covered by Medicare U.S.A. for Stage II-IV ovarian, fallopian tube, or primary peritoneal cancer in the adjuvant and recurrence monitoring settings.

Immunotherapy

Signatera™ is designed to longitudinally monitor molecular disease burden for patients on immunotherapy, providing an additional layer of insight alongside imaging and clinical evaluation.

Covered by Medicare for immune-checkpoint inhibitor treatment response monitoring across all solid tumor types and stages of cancer.